Adenine arabinoside 5′‐monophosphate treatment of chronic type B hepatitis

Jay H. Hoofnagle, Gerald Y. Minuk, Geoffrey M. Dusheiko, Daniel F. Schafer, Rodney Johnson, Stephen Straus, E. Anthony Jones, John L. Gerin, Kamal Ishak

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Six patients with chronic type B hepatitis were treated with adenine arabinoside 5′‐monophosphate at a dosage of 10 to 15 mg per kg per day for 10 days. All demonstrated an immediate and marked decrease in serum hepatitis B virus DNA and DNA polymerase, and 5 of the 6 became negative for both markers by the end of the period of therapy. One patient remained negative for hepatitis B virus DNA and DNA polymerase when therapy was discontinued. This patient subsequently exhibited clinical, serum biochemical, and histological remission in disease activity concurrent with seroconversion from hepatitis B e antigen to antibody. In the remaining five patients, serum hepatitis B virus DNA and DNA polymerase returned to pretreatment values soon after therapy was stopped, and these patients demonstrated no significant changes in clinical, biochemical, serological, or histological features of the disease. Side effects of the therapy were mild and transient. These results suggest that a 10‐day course of adenine arabinoside 5′‐monophosphate is not adequate to induce permanent amelioration of infection and disease activity in the majority of patients with chronic type B hepatitis.

Original languageEnglish (US)
Pages (from-to)784-788
Number of pages5
JournalHepatology
Volume2
Issue number6
DOIs
StatePublished - Jan 1 1982

Fingerprint

Vidarabine
Chronic Hepatitis B
DNA-Directed DNA Polymerase
Hepatitis B virus
DNA
Therapeutics
Serum
Hepatitis B e Antigens
Antibodies
Infection

ASJC Scopus subject areas

  • Hepatology

Cite this

Hoofnagle, J. H., Minuk, G. Y., Dusheiko, G. M., Schafer, D. F., Johnson, R., Straus, S., ... Ishak, K. (1982). Adenine arabinoside 5′‐monophosphate treatment of chronic type B hepatitis. Hepatology, 2(6), 784-788. https://doi.org/10.1002/hep.1840020606

Adenine arabinoside 5′‐monophosphate treatment of chronic type B hepatitis. / Hoofnagle, Jay H.; Minuk, Gerald Y.; Dusheiko, Geoffrey M.; Schafer, Daniel F.; Johnson, Rodney; Straus, Stephen; Jones, E. Anthony; Gerin, John L.; Ishak, Kamal.

In: Hepatology, Vol. 2, No. 6, 01.01.1982, p. 784-788.

Research output: Contribution to journalArticle

Hoofnagle, JH, Minuk, GY, Dusheiko, GM, Schafer, DF, Johnson, R, Straus, S, Jones, EA, Gerin, JL & Ishak, K 1982, 'Adenine arabinoside 5′‐monophosphate treatment of chronic type B hepatitis', Hepatology, vol. 2, no. 6, pp. 784-788. https://doi.org/10.1002/hep.1840020606
Hoofnagle JH, Minuk GY, Dusheiko GM, Schafer DF, Johnson R, Straus S et al. Adenine arabinoside 5′‐monophosphate treatment of chronic type B hepatitis. Hepatology. 1982 Jan 1;2(6):784-788. https://doi.org/10.1002/hep.1840020606
Hoofnagle, Jay H. ; Minuk, Gerald Y. ; Dusheiko, Geoffrey M. ; Schafer, Daniel F. ; Johnson, Rodney ; Straus, Stephen ; Jones, E. Anthony ; Gerin, John L. ; Ishak, Kamal. / Adenine arabinoside 5′‐monophosphate treatment of chronic type B hepatitis. In: Hepatology. 1982 ; Vol. 2, No. 6. pp. 784-788.
@article{5a9a77110fc3412e9b16365f0b8186d6,
title = "Adenine arabinoside 5′‐monophosphate treatment of chronic type B hepatitis",
abstract = "Six patients with chronic type B hepatitis were treated with adenine arabinoside 5′‐monophosphate at a dosage of 10 to 15 mg per kg per day for 10 days. All demonstrated an immediate and marked decrease in serum hepatitis B virus DNA and DNA polymerase, and 5 of the 6 became negative for both markers by the end of the period of therapy. One patient remained negative for hepatitis B virus DNA and DNA polymerase when therapy was discontinued. This patient subsequently exhibited clinical, serum biochemical, and histological remission in disease activity concurrent with seroconversion from hepatitis B e antigen to antibody. In the remaining five patients, serum hepatitis B virus DNA and DNA polymerase returned to pretreatment values soon after therapy was stopped, and these patients demonstrated no significant changes in clinical, biochemical, serological, or histological features of the disease. Side effects of the therapy were mild and transient. These results suggest that a 10‐day course of adenine arabinoside 5′‐monophosphate is not adequate to induce permanent amelioration of infection and disease activity in the majority of patients with chronic type B hepatitis.",
author = "Hoofnagle, {Jay H.} and Minuk, {Gerald Y.} and Dusheiko, {Geoffrey M.} and Schafer, {Daniel F.} and Rodney Johnson and Stephen Straus and Jones, {E. Anthony} and Gerin, {John L.} and Kamal Ishak",
year = "1982",
month = "1",
day = "1",
doi = "10.1002/hep.1840020606",
language = "English (US)",
volume = "2",
pages = "784--788",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Adenine arabinoside 5′‐monophosphate treatment of chronic type B hepatitis

AU - Hoofnagle, Jay H.

AU - Minuk, Gerald Y.

AU - Dusheiko, Geoffrey M.

AU - Schafer, Daniel F.

AU - Johnson, Rodney

AU - Straus, Stephen

AU - Jones, E. Anthony

AU - Gerin, John L.

AU - Ishak, Kamal

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Six patients with chronic type B hepatitis were treated with adenine arabinoside 5′‐monophosphate at a dosage of 10 to 15 mg per kg per day for 10 days. All demonstrated an immediate and marked decrease in serum hepatitis B virus DNA and DNA polymerase, and 5 of the 6 became negative for both markers by the end of the period of therapy. One patient remained negative for hepatitis B virus DNA and DNA polymerase when therapy was discontinued. This patient subsequently exhibited clinical, serum biochemical, and histological remission in disease activity concurrent with seroconversion from hepatitis B e antigen to antibody. In the remaining five patients, serum hepatitis B virus DNA and DNA polymerase returned to pretreatment values soon after therapy was stopped, and these patients demonstrated no significant changes in clinical, biochemical, serological, or histological features of the disease. Side effects of the therapy were mild and transient. These results suggest that a 10‐day course of adenine arabinoside 5′‐monophosphate is not adequate to induce permanent amelioration of infection and disease activity in the majority of patients with chronic type B hepatitis.

AB - Six patients with chronic type B hepatitis were treated with adenine arabinoside 5′‐monophosphate at a dosage of 10 to 15 mg per kg per day for 10 days. All demonstrated an immediate and marked decrease in serum hepatitis B virus DNA and DNA polymerase, and 5 of the 6 became negative for both markers by the end of the period of therapy. One patient remained negative for hepatitis B virus DNA and DNA polymerase when therapy was discontinued. This patient subsequently exhibited clinical, serum biochemical, and histological remission in disease activity concurrent with seroconversion from hepatitis B e antigen to antibody. In the remaining five patients, serum hepatitis B virus DNA and DNA polymerase returned to pretreatment values soon after therapy was stopped, and these patients demonstrated no significant changes in clinical, biochemical, serological, or histological features of the disease. Side effects of the therapy were mild and transient. These results suggest that a 10‐day course of adenine arabinoside 5′‐monophosphate is not adequate to induce permanent amelioration of infection and disease activity in the majority of patients with chronic type B hepatitis.

UR - http://www.scopus.com/inward/record.url?scp=0020448882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020448882&partnerID=8YFLogxK

U2 - 10.1002/hep.1840020606

DO - 10.1002/hep.1840020606

M3 - Article

C2 - 6183183

AN - SCOPUS:0020448882

VL - 2

SP - 784

EP - 788

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -